FOR IMMEDIATE RELEASE September 8, 2020, 1:00 pm EDT Contact: John M. Clymer Executive Director 202-903-7303 What Do Value & Access Really Mean? New report documents changes in stakeholder perspectives and what the terms mean in 2020 Washington, D.C. – The National Forum for Heart Disease & Stroke …
Call to Expand Access to Tests, Vaccinations Grows Louder
FOR IMMEDIATE RELEASE August 21, 2020, 1:00 pm EDT Contact: John M. Clymer Executive Director 202-903-7303 More Patient Groups Appeal to Congress to Fix Glitch So Americans Have Access to COVID and Flu Testing and Vaccinations Patient groups urging action in next COVID bill represent 200 million …
A Real Way to Strengthen the U.S. Response to COVID-19 That’s Ready to Roll
John M. Clymer Executive Director National Forum for Heart Disease & Stroke Prevention As Congress and the Trump Administration negotiate over the next COVID-19 legislative package, they have an opportunity to strengthen the nation’s response to the pandemic, blunt the health impact of COVID-19 and, at the same time, increase health …
National Forum and Partners Call on Congress and President to Expand Access to Care in COVID-19 Bill
EMBARGOED Until August 6, 2020, 12:30 pm EDT Contact: John M. Clymer Executive Director 202-903-7303 Patients, Consumers, the Underserved, Healthcare Providers and Public Health Call on Congress to Fix a Missing Link So Pharmacies Can Ramp Up COVID Testing and Prepare for Vaccinations Patient groups …
Value & Access Steering Committee & Partners Provide Consensus Feedback on ICER Draft Scope of High Cholesterol Treatments
The National Forum’s Value & Access Initiative Steering Committee and partners engaged in the value & access space provided consensus feedback on the Institute for Clinical and Economic Review (ICER)’s draft scope of the assessment of the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol™, …
Value & Access Steering Committee & Partners Provide Input on ICER Draft Scope of High Cholesterol Treatments
The National Forum’s Value & Access Initiative Steering Committee and partners engaged in the value & access space provided input on the Institute for Clinical and Economic Review (ICER)’s scope of the upcoming assessment of the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol™, Esperion …
Replay Available -Uptake and Pricing of Biosimilars & the “Rebate Wall” Multi-Perspective Briefing Presented by the Value & Innovation Forum
ABOUT The Value & Innovation Forum helps patients, providers and other health system stakeholders address timely, complex issues by conducting briefings that present a variety of perspectives. A June 2, 2020 briefing covered the uptake and pricing of biosimilars, and delivery system …
National Forum and Partners Urge Congress and Administration to Increase Patients’ Access to Healthcare, Team-Based Care
For release Tuesday, June 16, 2020, 12 pm EDT For information contact John M. Clymer, Executive Director, 202-903-7303 or john.clymer@nationalforum.org NATIONAL FORUM AND PARTNERS URGE CONGRESS AND ADMINISTRATION TO INCREASE PATIENTS’ ACCESS TO HEALTHCARE, TEAM-BASED CARE Today, the National Forum for Heart Disease & Stroke Prevention and …
National Forum Statement about ICER’s Announced Assessment of New Cholesterol Medications
The National Forum released the following statement about the Institute for Clinical and Economic Review’s (ICER’s) announcement today that it will conduct value assessments of inclisiran and bempadoic acid, two new treatments for high cholesterol. The Value & Access Steering Committee (VASC), convened by the National Forum and representing …